$ABOS Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.35 up 20.45% YoY
• Acumen Pharmaceuticals expects its $78.6M in cash, cash equivalents and marketable securities as of September 30, 2026, to support current clinical and operational activities into early 2027.